Deerfield Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Deerfield Management’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-870,000	Closed	-$13.9M	–	120
2022 Q3	$13.9M	Buy	+870,000	New	+$13.6M	0.28%	74
2020 Q3	–	Sell	-53,043	Closed	-$1.11M	–	112
2020 Q2	$1.11M	Sell	53,043 -1,624,324	-97%	-$29.3M	0.03%	90
2020 Q1	$23.4M	Sell	1,677,367 -487,104	-23%	-$9.65M	0.74%	43
2019 Q4	$49.3M	Buy	2,164,471 +390,533	+22%	+$6.52M	1.57%	22
2019 Q3	$20.7M	Buy	1,773,938 +636,796	+56%	+$7.9M	0.84%	39
2019 Q2	$17.1M	Buy	1,137,142 +857,142	+306%	+$15M	0.61%	57
2019 Q1	$4.91M	Hold	280,000	–	–	0.19%	72
2018 Q4	$4.15M	Hold	280,000	–	–	0.17%	78
2018 Q3	$6.89M	Hold	280,000	–	–	0.25%	82
2018 Q2	$5.5M	Sell	280,000 -120,000	-30%	-$2.27M	0.19%	97
2018 Q1	$7.5M	Buy	+400,000	New	+$6.52M	0.26%	91

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Deerfield Management's RCKT Position: Q4 2022 in Review

Deerfield Management sold out of Rocket Pharmaceuticals (RCKT) in Q4 2022, closing a stake of 870,000 shares — an estimated $13.9M sold.

Deerfield Management first reported a position in RCKT in Q1 2018 and held it in 11 quarters. The position peaked at $49.3M in Q4 2019. 167 funds tracked by Wall St. Rank hold RCKT as of Q4 2022.

Deerfield Management reported no remaining Rocket Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Deerfield Management sold 870,000 Rocket Pharmaceuticals shares in Q4 2022, an estimated $13.9M.
Deerfield Management first reported a position in Rocket Pharmaceuticals in Q1 2018 and held it in 11 quarters.
Deerfield Management's Rocket Pharmaceuticals position peaked at $49.3M in Q4 2019.
167 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2022.

Based on Deerfield Management's 13F filing for Q4 2022, filed 14 Feb 2023.